- Home
- CORT vs HALO Comparison
CORT vs HALO Comparison
Compare CORT & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CORT
- HALO
- Stock Information
- Founded
- CORT 1998
- HALO 1998
- Country
- CORT United States
- HALO United States
- Employees
- CORT N/A
- HALO N/A
- Industry
- CORT Biotechnology: Pharmaceutical Preparations
- HALO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CORT Health Care
- HALO Health Care
- Exchange
- CORT Nasdaq
- HALO Nasdaq
- Market Cap
- CORT 7.1B
- HALO 7.4B
- IPO Year
- CORT N/A
- HALO N/A
- Fundamental
- Price
- CORT $70.59
- HALO $50.23
- Analyst Decision
- CORT Strong Buy
- HALO Buy
- Analyst Count
- CORT 4
- HALO 9
- Target Price
- CORT $142.00
- HALO $63.78
- AVG Volume (30 Days)
- CORT 1.4M
- HALO 2.6M
- Earning Date
- CORT 05-05-2025
- HALO 05-06-2025
- Dividend Yield
- CORT N/A
- HALO N/A
- EPS Growth
- CORT 8.36
- HALO 55.40
- EPS
- CORT 1.14
- HALO 3.76
- Revenue
- CORT $685,446,000.00
- HALO $1,084,306,000.00
- Revenue This Year
- CORT $35.85
- HALO $24.79
- Revenue Next Year
- CORT $35.22
- HALO $22.65
- P/E Ratio
- CORT $61.82
- HALO $13.36
- Revenue Growth
- CORT 30.93
- HALO 25.64
- 52 Week Low
- CORT $25.35
- HALO $41.28
- 52 Week High
- CORT $117.33
- HALO $70.51
- Technical
- Relative Strength Index (RSI)
- CORT 50.86
- HALO 34.42
- Support Level
- CORT $69.33
- HALO $58.38
- Resistance Level
- CORT $73.36
- HALO $69.94
- Average True Range (ATR)
- CORT 3.66
- HALO 3.30
- MACD
- CORT -0.20
- HALO -0.27
- Stochastic Oscillator
- CORT 39.15
- HALO 9.30
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.